Effect of JGK-263 as a new glycogen synthase kinase-3 beta inhibitor on extrinsic apoptosis pathway in motor neuronal cells

Abstract

Glycogen synthase kinase-3 beta (GSK-3 beta) has been identified as one of the important pathogenic mechanisms in motor neuronal death. GSK-3 beta inhibitor has been investigated as a modulator of apoptosis and has been shown to confer significant protective effects on cell death in neurodegenerative diseases. However, GSK-3 beta is known to have paradoxical effects on apoptosis subtypes, i.e., pro-apoptotic in mitochondrial-associated intrinsic apoptosis, but anti-apoptotic in death receptor-related extrinsic apoptosis. In this study, we evaluated the effect of a new GSK-3 beta inhibitor (JGK-263) on motor neuron cell survival and apoptosis, by using low to high doses of JGK-263 after 48 h of serum withdrawal, and monitoring changes in extrinsic apoptosis pathway components, including Fas, FasL, cleaved caspase-8, p38 alpha, and the Fas-Daxx interaction. Cell survival peaked after treatment of serum-deprived cells with 50 mu M JGK-263. The present study showed that treatment with JGK-263 reduced serum-deprivation-induced motor neuronal apoptosis by inactivating not only the intrinsic, but also the extrinsic apoptosis pathway. These results suggest that JGK-263 has a neuroprotective effect through effective modulation of the extrinsic apoptosis pathway in motor neuron degeneration.